Sarepta Therapeutics Inc (NASDAQ:SRPT) has been given an average recommendation of “Buy” by the twenty-one analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $206.82.
Several equities analysts recently commented on the stock. ValuEngine downgraded shares of WideOpenWest from a “hold” rating to a “sell” rating in a report on Friday, June 28th. Citigroup set a $6.00 price target on shares of Solid Biosciences and gave the company a “hold” rating in a report on Thursday, May 16th. Cowen reiterated a “buy” rating and set a $77.00 price target on shares of Centene in a report on Sunday, March 31st. Zacks Investment Research downgraded shares of Haynes International from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Finally, HC Wainwright set a $267.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, June 17th.
In other news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total value of $1,200,000.00. Following the sale, the director now owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in SRPT. Evolution Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics during the second quarter valued at $25,000. Lindbrook Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $35,000. Quad Cities Investment Group LLC grew its position in shares of Sarepta Therapeutics by 100.0% in the first quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 200 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $51,000. Finally, Manchester Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $68,000. Institutional investors own 94.36% of the company’s stock.
Shares of Sarepta Therapeutics stock traded up $1.41 during trading hours on Friday, reaching $154.66. The company’s stock had a trading volume of 24,056 shares, compared to its average volume of 1,616,376. The business’s 50 day simple moving average is $134.39. Sarepta Therapeutics has a one year low of $95.21 and a one year high of $165.87. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. The stock has a market cap of $11.44 billion, a PE ratio of -28.26 and a beta of 2.12.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The firm had revenue of $87.01 million for the quarter, compared to the consensus estimate of $86.92 million. Research analysts anticipate that Sarepta Therapeutics will post -4.04 earnings per share for the current fiscal year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Further Reading: Hedge Funds – How They Work For Investors
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.